Both Croda International and Novasep are involved in some of the vaccines nearing approval for use in the treatment of COVID-19 it has emerged. This follows on from many other announcements of development agreements involving other fine chemical companies earlier in the year.
Lonza has opened the first of two manufacturing suites at its main site in Visp, Switzerland, for the manufacture of antibody-drug conjugate (ADC) linkers or payloads. This came shortly after an unrelated deal to manufacture antibodies to treat COVID-19 for AstraZeneca and the arrival of a new CEO with a Big Pharma background.
Ineos used the occasion of the British Grand Prix on 1 August, where it was sponsoring the Mercedes team, to launch Ineos Hygienics, its new global healthcare business. This will be based at Newton Aycliffe, UK, and produce hospital grade hand gels, sanitiser sprays for hands and surfaces and sanitiser wipes out of the facilities the firm converted earliest this year here and in France, Germany and the US.
The ongoing race to develop the first effective vaccines for the treatment of COVID-19 continues to generate manufacturing and development agreements between pharmaceutical giants, biotechs and CDMOs.
Most recently, Sterling Pharma Solutions agreed to carry out final purification of drug product for Moleculin Biotech’s WP1122 drug candidate from its site in Cary, North Carolina. Moleculin is about to submit an IND for this to the FDA and wanted a reliable source of supply in the US.
Paige Marie Morse, industry director of chemicals at AspenTech, looks at how chemical companies can use digitalisation to navigate in uncertain times
The current pandemic has presented chemical producers over the world with a raft of complex challenges. Across the industry, companies are being tested for their agility in learning how to navigate huge shifts in demand, supply, workforce and economics, as well as of their operational resilience and how they plan to emerge in a stronger position.
Feature article - Three ways the chemicals & materials industry can benefit from digital transformation
Dr Nina Kaun, product director, chemical industry solutions, at Elsevier, looks at how the Covid-19 pandemic could help to drive digitalisation
While many industries have taken advantage of technology developments in recent years, the chemicals and materials sector has been slower to digitalise. This attitude is now changing: 87% of chemicals and materials executives believe companies will ‘lose their edge’ or ‘face extinction’ unless they embrace digital transformation, including adopting more automation and applying artificial intelligence (AI) to some processes.
Dr Russel Walters, freelance scientist at Kolabtree, shares his expertise on how to start manufacturing a hand sanitiser quickly, easily and compliantly
In order for a virus to infect a human host, the host needs to be exposed to a sufficient viral load, typically hundreds, thousands or tens of thousands of viral particles. Hand sanitisers dramatically reduce the viral load on the skin and therefore can reduce infections or perhaps infection severity.